EVIVE Biotechnology
As of the edition of 20 October 2026, EVIVE Biotechnology runs 2 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Efbemalenograstim alfa | Ends 2035 (computed from the first US licence) | 2 |
A route B row is one company at one target.
Where its trials are
- Blood and lymph: 7 trials led
- Cancer: 5 trials led
- Skin and connective tissue: 5 trials led